Tumor necrosis factor receptor
From Proteopedia
(Difference between revisions)
| Line 12: | Line 12: | ||
* '''TNFRSF 10''' see [[TRAIL]];<br /> | * '''TNFRSF 10''' see [[TRAIL]];<br /> | ||
* '''TNFRSF 10B''' is called '''Dr5''';<br /> | * '''TNFRSF 10B''' is called '''Dr5''';<br /> | ||
| - | * '''TNFRSF 11''' is called '''RANKL''';<br /> | ||
* '''TNFRSF 11A''' is called '''RANK''';<br /> | * '''TNFRSF 11A''' is called '''RANK''';<br /> | ||
* '''TNFRSF 11B''' is called '''Osteoprotegerin''';<br /> | * '''TNFRSF 11B''' is called '''Osteoprotegerin''';<br /> | ||
* '''TNFRSF 12''' is called '''TWEAK''';<br /> | * '''TNFRSF 12''' is called '''TWEAK''';<br /> | ||
* '''TNFRSF 12A''' is called '''TWEAKR''';<br /> | * '''TNFRSF 12A''' is called '''TWEAKR''';<br /> | ||
| - | * '''TNFRSF 13''' is called '''APRIL''';<br /> | ||
* '''TNFRSF 13B''' is called '''BAFF or sTALL-1''';<br /> | * '''TNFRSF 13B''' is called '''BAFF or sTALL-1''';<br /> | ||
* '''TNFRSF 13C''' is called '''BAFF receptor''';<br /> | * '''TNFRSF 13C''' is called '''BAFF receptor''';<br /> | ||
| Line 67: | Line 65: | ||
**[[1aly]] – hTNFSF-5 extracellular domain <BR /> | **[[1aly]] – hTNFSF-5 extracellular domain <BR /> | ||
| - | **[[1i9r]], [[5dmi]], [[ | + | **[[1i9r]], [[5dmi]], [[5ihl]] – hTNFSF-5 extracellular domain + antibody<BR /> |
| - | **[[3lkj]] – hTNFSF-5 extracellular domain + inhibitor<BR /> | + | **[[5dmj]] – hTNFRSF-5 extracellular domain (mutant) + antibody<br /> |
| + | **[[3lkj]], [[5ihl]] – hTNFSF-5 extracellular domain + inhibitor<BR /> | ||
**[[3qd6]] – hTNFRSF-5 extracellular domain + CD40 ligand<br /> | **[[3qd6]] – hTNFRSF-5 extracellular domain + CD40 ligand<br /> | ||
| Line 97: | Line 96: | ||
**[[4n90]] – hTNFRSF-10B + hTNFRSF-10 + antibody <br /> | **[[4n90]] – hTNFRSF-10B + hTNFRSF-10 + antibody <br /> | ||
| - | *Tumor necrosis factor receptor superfamily-11 | + | *Tumor necrosis factor receptor superfamily-11 |
**[[1jtz]], [[1iqa]], [[1s55]] – mTNFSF-11 receptor-binding domain<BR /> | **[[1jtz]], [[1iqa]], [[1s55]] – mTNFSF-11 receptor-binding domain<BR /> | ||
**[[3me2]], [[3qbq]], [[4giq]] – mTNFSF-11 receptor-binding domain + RANK <BR /> | **[[3me2]], [[3qbq]], [[4giq]] – mTNFSF-11 receptor-binding domain + RANK <BR /> | ||
| - | **[[4e4d]] – mTNFSF-11 receptor-binding domain + osteoprotegerin<BR /> | ||
| - | **[[3urf]] – hTNFSF-11 receptor-binding domain + osteoprotegerin<BR /> | ||
*Tumor necrosis factor receptor superfamily-11A (RANK) | *Tumor necrosis factor receptor superfamily-11A (RANK) | ||
| Line 111: | Line 108: | ||
*Tumor necrosis factor receptor superfamily-11B (Osteoprotegerin) | *Tumor necrosis factor receptor superfamily-11B (Osteoprotegerin) | ||
| - | **[[3urf]] – hTNFRSF-11B extracellular domain + | + | **[[3urf]] – hTNFRSF-11B extracellular domain + RANKL<br /> |
| - | **[[4e4d]] – mTNFRSF-11B extracellular domain + | + | **[[4e4d]] – mTNFRSF-11B extracellular domain + RANKL<br /> |
*TNFSF-12 superfamily member 12 (TWEAK) | *TNFSF-12 superfamily member 12 (TWEAK) | ||
| Line 121: | Line 118: | ||
**[[2rpj]], [[2kmz]], [[2epq]] – hTNFRSF-12A cysteine-rich domain – NMR <br /> | **[[2rpj]], [[2kmz]], [[2epq]] – hTNFRSF-12A cysteine-rich domain – NMR <br /> | ||
| - | |||
| - | *TNFSF-13 superfamily member 13 (APRIL) | ||
| - | |||
| - | **[[1u5x]], [[1u5y]], [[1u5z]] – mTNFSF-13 extracellular domain <BR /> | ||
| - | **[[1xu1]] – mTNFSF-13 extracellular domain + TNFSF-13B <BR /> | ||
| - | **[[1xu2]] – mTNFSF-13 extracellular domain + BCMA <BR /> | ||
| - | **[[3k48]] – mTNFSF-13 extracellular domain + peptide<BR /> | ||
| - | **[[4zch]] – hTNFSF-13 extracellular domain + TNFSF-13B <BR /> | ||
*TNFSF-13B superfamily member 13B (BAFF, sTALL-1) | *TNFSF-13B superfamily member 13B (BAFF, sTALL-1) | ||
| Line 137: | Line 126: | ||
**[[4v46]] – hTNFSF-13B extracellular domain + hTNFRSF-13C + BAFF<BR /> | **[[4v46]] – hTNFSF-13B extracellular domain + hTNFRSF-13C + BAFF<BR /> | ||
**[[1osg]], [[3v56]] – hTNFSF-13B extracellular domain + hTNFRSF-13C peptide <BR /> | **[[1osg]], [[3v56]] – hTNFSF-13B extracellular domain + hTNFRSF-13C peptide <BR /> | ||
| + | **[[1xu1]] – hTNFRSF-13B extracellular domain + APRIL <br /> | ||
*Tumor necrosis factor receptor superfamily-13C (BAFF receptor) | *Tumor necrosis factor receptor superfamily-13C (BAFF receptor) | ||
**[[1osx]] – hTNFRSF-13C extracellular domain - NMR <br /> | **[[1osx]] – hTNFRSF-13C extracellular domain - NMR <br /> | ||
| - | **[[2hfg]] – | + | **[[2hfg]] – hTNFRSF-13C cysteine-rich domain + antibody<BR /> |
*Tumor necrosis factor receptor superfamily-14 (LIGHT) | *Tumor necrosis factor receptor superfamily-14 (LIGHT) | ||
| Line 165: | Line 155: | ||
**[[2kn1]] – hTNFRSF-17 extracellular domain - NMR <br /> | **[[2kn1]] – hTNFRSF-17 extracellular domain - NMR <br /> | ||
**[[4zfo]] – hTNFRSF-17 extracellular domain + antibody <br /> | **[[4zfo]] – hTNFRSF-17 extracellular domain + antibody <br /> | ||
| + | **[[1xu2]] – hTNFRSF-17 extracellular domain + APRIL <br /> | ||
*Tumor necrosis factor receptor superfamily-18 (GITRL) | *Tumor necrosis factor receptor superfamily-18 (GITRL) | ||
Revision as of 22:07, 12 October 2017
| |||||||||||
3D structures of tumor necrosis factor receptor
Updated on 12-October-2017
References
- ↑ Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol. 1999;17:331-67. PMID:10358762 doi:http://dx.doi.org/10.1146/annurev.immunol.17.1.331
- ↑ Lopalco G, Rigante D, Vitale A, Frediani B, Iannone F, Cantarini L. Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol. 2015 Apr;34(4):807-9. doi: 10.1007/s10067-014-2556-8. Epub 2014, Mar 11. PMID:24609716 doi:http://dx.doi.org/10.1007/s10067-014-2556-8
- ↑ Naismith JH, Devine TQ, Kohno T, Sprang SR. Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure. 1996 Nov 15;4(11):1251-62. PMID:8939750
